Therapeutic Compounds

A compound of formula (I),

• wherein:
• R1, R2,—R3, R4 are independently selected from hydrogen, C1-C6 alkyl, —(CR12aR12b)thalo, —(CR12aR12b)tCN, —(CR12aR12b)tOR, —(CR12aR12b)tN(R12aR12b), —(CR12aR12b)tCF3, and —(CR12aR12b)tC6-C10 aryl;
• R5 is hydrogen or C1-C6 alkyl;
• R6, R7, R8 and R9 are independently selected from hydrogen, C1-C6 alkyl, —(CR12aR12b)thalo, —(CR12aR12b)tCN, —(CR12aR12b)tCF3, —(CR12aR12b)tOR12a, —(CR12aR12b)tN(R12aR12b), —(CR—(CR12aR12b)tC3-C11 cycloalkyl, —(CR12aR12b)tC6-C10 aryl, —(CR12aR12b)tC2-C10 heterocyclyl,—(CR12aR12b)theteroaryl, —O(CR12aR12b)tR12a, —O(CR12aR12b)tC3-C cycloalkyl, —O(CR12aR12b)tC6-C10 aryl, —O(CR12aR12b)tC2-C10 heterocyclyl, —O(CR12aR12b)theteroaryl, —O(CR12aR12b)tOR12a, —O(CR12aR12b)tN(R12aR12b), wherein each of said C1-C6 alkyl, C3-C11 cycloalkyl, C6-C10 aryl, heterocyclyl, and heteroaryl is optionally substituted with one or more R14;
• R10 and R11 are independently selected from hydrogen, —(CR12aR12b)tC1-C6 alkyl, —(CR12aR12b)tC3-C11 —cycloalkyl, —(CR12aR12b)tC6-C10 aryl, —(CR12aR12b)tC2-C10 heterocyclyl, and —(CR12aR12b) wherein each of said C1-C6 alkyl, C3-C11 cycloalkyl, C6-C10 aryl, C2-C10 heterocyclyl, and heteroaryl groups is optionally substituted with one or more R13;
• or
• R10 and R11, together with the atom to which they are attached, form a C2-C10 heterocyclyl group, optionally substituted with one or more R13;
• each R12a and R12b is independently selected from hydrogen and C1-C6 alkyl;
• or
• R12a and R12b together with the atom to which they are attached, form a C3-C11 cycloalkyl or a C2-C10 heterocyclyl group;
• each R13 is independently selected from C1-C6 alkyl, halogen, —(CR12aR12b)tCN, —(CR12aR12b)tCF3, —(CR12aR12b)tOCF3, —(CR12aR12b)tC3-C11 cycloalkyl, —(CR12aR12b)tC6-C10 aryl, —(CR12aR12b)tC2-C10 heterocyclyl, —(CR12aR12b)theteroaryl, —O(CR12aR12b)tR12a, —O(CR12aR12b)tC6-C10 aryl, —O(CR12aR12b)tC2-C10 heterocyclyl, —O(CR12aR12b)theteroaryl, —(CR12a R12b)tCO2(C1-C6 alkyl), —(CR12aR12b)tN(R12aR12b), —(CR12aR12b)tC(O)NR12aR12b, —(CR12aR12b)tOR12a, —(CR12aR12b)tS(O)R12a, and —(CR12aR12b)tS(O)2R12a, wherein each of said C1-C6 alkyl, C3-C11 cycloalkyl, C6-C10 aryl, C2-C10 heterocyclyl, and heteroaryl groups is optionally substituted with one or more R14;
• each R14 is independently selected from C1-C6 alkyl, halogen, —CN, —CF3, and —OR12a;
• and
• each t is independently selected from 0, 1, 2, 3, 4, 5, and 6;
• or
• a pharmaceutically acceptable salt or solvate thereof.